SequelSEC

Compass Therapeutics, Inc. CMPX

Biological Products, (No Diagnostic Substances) · CIK 0001738021 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$72.84M
Fiscal year ended 2025-12-31
Free cash flow
-$49.17M
Fiscal year ended 2025-12-31

Compass Therapeutics, Inc. (CMPX) reported revenue of $0 and net income of -$66.49M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Compass Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Compass Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Revenue$0$850.00K$0
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$72.84M-$56.62M-$50.36M
Net income-$66.49M-$49.38M-$42.49M
Research & development$55.97M$42.34M$38.12M
Weighted-average diluted sharesUnavailableshares 137.40MUnavailable
Pretax incomeUnavailableUnavailable-$42.49M
Income tax expense$0$0$0
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$16.87M$15.13M$12.24M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Compass Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$30.64M$43.48M$24.23M
Total assets$219.59M$140.40M$156.88M
Current assets$209.82M$132.75M$153.88M
Total liabilities$22.80M$15.17M$8.34M
Current liabilities$13.97M$8.87M$7.80M
Total equity incl. NCI$196.79M$125.23M$148.54M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.58M$2.25M$4.09M

Cash flow

Compass Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$49.14M-$44.86M-$40.62M
Capital expenditures$25.00K$44.00K$30.00K
Investing cash flow-$93.31M$46.77M$26.96M
Financing cash flow$129.61M$17.34M$2.94M
Net change in cash-$12.84M$19.26M-$10.72M
Stock-based compensation$8.37M$8.56M$6.12M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$276.00K$589.00K$699.00K

Derived

Compass Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$49.17M-$44.90M-$40.65M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailable-6661.8%Unavailable
FCF marginUnavailable-5282.2%Unavailable
SBC / revenueUnavailable1007.1%Unavailable
Current ratio15.02x14.96x19.73x
Revenue YoY growth-100.0%UnavailableUnavailable
Net marginUnavailable-5808.8%Unavailable
R&D / revenueUnavailable4981.4%Unavailable
CapEx / revenueUnavailable5.2%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CMPX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.